Baxter is launching its new dialysis technology, HDx enabled by THERANOVA, in a global release of the new technology.
HDx stands for “expanded hemodialysis” and, as the name implies, the THERANOVA dialyzer that powers it is able to filter a wider range of molecules compared to traditional dialysis. The company claims that the filtering ability of THERANOVA more closely mimics healthy kidneys.
The new dialyzer filters out larger mid-sized molecules that conventional dialysis tends to leave back in patient blood. Outcomes should be improved for patients with kidney failure, potentially lowering the incidence of cardiovascular and other types of conditions.
THERANOVA is compatible with most existing dialysis systems and does not require any changes in equipment, procedures, or processes, allowing clinics to adopt the technology with almost no upfront costs.
HDx enabled by THERANOVA is not yet available in the U.S.
Led by Alexander R. Rosenkranz, M.D., Clinical Division of Nephrology, Medical University of Graz, Austria, and Detlef H. Krieter, M.D., Division of Nephrology, University Hospital Würzburg, Germany, researchers conducted two prospective, randomized, crossover pilot studies in three dialysis centers in Austria and Germany.
A total of 39 patients were included. The studies focused on clearance of free immunoglobulin light chains (FLC), as FLC levels have been associated with increased mortality risk in chronic kidney disease6 and high-flux dialyzers are limited in their ability to remove these molecules. The study found that THERANOVA had higher clearance of middle molecules including FLCs, compared to both HD and HDF.